Anaplastic Thyroid Cancer - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Thyroid Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H1 2015', provides an overview of the Anaplastic Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Thyroid Cancer - Overview 8
Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9
Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10
Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anaplastic Thyroid Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Anaplastic Thyroid Cancer - Products under Development by Companies 14
Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16
Daiichi Sankyo Company, Limited 16
Exelixis, Inc. 17
Genelux Corporation 18
GlaxoSmithKline plc 19
Immune Pharmaceuticals, Ltd. 20
Novartis AG 21
OXiGENE, Inc. 22
Plexxikon Inc. 23
Takeda Oncology 24
Anaplastic Thyroid Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cabozantinib s-malate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ceritinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CLM-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CLM-94 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
crolibulin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
efatutazone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
fosbretabulin tromethamine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GLONC-2 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MLN-0128 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PLX-8394 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Anaplastic Thyroid Cancer - Recent Pipeline Updates 56
Anaplastic Thyroid Cancer - Dormant Projects 79
Anaplastic Thyroid Cancer - Product Development Milestones 80
Featured News & Press Releases 80
Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2015 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 16
Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2015 17
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H1 2015 18
Anaplastic Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 19
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 20
Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H1 2015 21
Anaplastic Thyroid Cancer - Pipeline by OXiGENE, Inc., H1 2015 22
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2015 23
Anaplastic Thyroid Cancer - Pipeline by Takeda Oncology, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Assessment by Combination Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015 56
Anaplastic Thyroid Cancer - Dormant Projects, H1 2015 79